| Product NDC: | 44206-454 |
| Proprietary Name: | Hizentra |
| Non Proprietary Name: | HUMAN IMMUNOGLOBULIN G |
| Active Ingredient(s): | .2 g/mL & nbsp; HUMAN IMMUNOGLOBULIN G |
| Administration Route(s): | SUBCUTANEOUS |
| Dosage Form(s): | LIQUID |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 44206-454 |
| Labeler Name: | CSL Behring AG |
| Product Type: | PLASMA DERIVATIVE |
| FDA Application Number: | BLA125350 |
| Marketing Category: | BLA |
| Start Marketing Date: | 20111003 |
| Package NDC: | 44206-454-04 |
| Package Description: | 1 VIAL, SINGLE-DOSE in 1 CARTON (44206-454-04) > 20 mL in 1 VIAL, SINGLE-DOSE (44206-454-92) |
| NDC Code | 44206-454-04 |
| Proprietary Name | Hizentra |
| Package Description | 1 VIAL, SINGLE-DOSE in 1 CARTON (44206-454-04) > 20 mL in 1 VIAL, SINGLE-DOSE (44206-454-92) |
| Product NDC | 44206-454 |
| Product Type Name | PLASMA DERIVATIVE |
| Non Proprietary Name | HUMAN IMMUNOGLOBULIN G |
| Dosage Form Name | LIQUID |
| Route Name | SUBCUTANEOUS |
| Start Marketing Date | 20111003 |
| Marketing Category Name | BLA |
| Labeler Name | CSL Behring AG |
| Substance Name | HUMAN IMMUNOGLOBULIN G |
| Strength Number | .2 |
| Strength Unit | g/mL |
| Pharmaceutical Classes | Human Immunoglobulin G [EPC],Passively Acquired Immunity [PE],Antigen Neutralization [MoA],Immunoglobulins [Chemical/Ingredient] |